We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms. I Agree
FE Trustnet UK  |  FE Trustnet Offshore  |  FE Trustnet Hong Kong  |  FE Analytics  |  FE Fundlistings
rss Rss  |  About Us  |  Contact Us  |  Help
 Information  X 
Enter a valid email address
Show me how to log in   Forgot password?

Company Name matching 'ObsEva SA'

Date
Time Source
Company
Announcement
 
12 Jul 2019 6:00 am GNW     ObsEva SA ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
08 Jul 2019 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
01 Jul 2019 6:00 am GNW     ObsEva SA ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
21 Jun 2019 6:00 am GNW     ObsEva SA ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
19 Jun 2019 6:00 am GNW     ObsEva SA ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
04 Jun 2019 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
16 May 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
09 May 2019 6:15 am GNW     ObsEva SA ObsEva Reports First Quarter 2019 Financial Results
  6:00 am GNW     ObsEva SA ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
08 May 2019 9:30 pm GNW     ObsEva SA ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
03 May 2019 6:00 am GNW     ObsEva SA ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
01 May 2019 6:00 am GNW     ObsEva SA ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
29 Apr 2019 6:00 am GNW     ObsEva SA ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
01 Apr 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
29 Mar 2019 6:00 am GNW     ObsEva SA Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
13 Mar 2019 6:00 am GNW     ObsEva SA ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
05 Mar 2019 6:00 am GNW     ObsEva SA ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
27 Feb 2019 6:00 am GNW     ObsEva SA ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
22 Feb 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in Upcoming Investor Conferences
23 Jan 2019 8:28 am GNW     ObsEva SA Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
02 Jan 2019 6:00 am GNW     ObsEva SA ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
21 Dec 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
07 Dec 2018 5:12 pm GNW     ObsEva SA ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
06 Dec 2018 6:00 am GNW     ObsEva SA ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
29 Nov 2018 6:30 am GNW     ObsEva SA ObsEva SA to Host R&D Investor Day December 7, 2018
28 Nov 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
08 Nov 2018 6:15 am GNW     ObsEva SA ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
07 Nov 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in November Investor Conferences
31 Oct 2018 6:30 am GNW     ObsEva SA ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018
09 Oct 2018 9:15 pm GNW     ObsEva SA ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
05 Oct 2018 6:00 am GNW     ObsEva SA ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
03 Oct 2018 6:00 am GNW     ObsEva SA ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
28 Sep 2018 6:00 am GNW     ObsEva SA Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
28 Aug 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in September Investor Conferences
10 Aug 2018 6:30 am GNW     ObsEva SA ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018
08 Aug 2018 6:00 am GNW     ObsEva SA ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update
31 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
25 Jul 2018 6:30 am GNW     ObsEva SA ObsEva Expands Executive Team Hiring a Chief Commercial Officer
13 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA to start trading today on the SIX Swiss Exchange
06 Jul 2018 6:30 am GNW     ObsEva SA ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
20 Jun 2018 7:49 am GNW     ObsEva SA ObsEva Announces Pricing of Follow-on Public Offering
18 Jun 2018 9:31 pm GNW     ObsEva SA ObsEva Announces Launch of Proposed Follow-on Public Offering
  12:00 pm GNW     ObsEva SA ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
15 Jun 2018 9:00 pm GNW     ObsEva SA ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
01 Jun 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Seek SIX Share Listing
31 May 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
16 May 2018 12:00 pm GNW     ObsEva SA ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
08 May 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
23 Apr 2018 12:00 pm GNW     ObsEva SA ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
16 Apr 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
26 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018
09 Mar 2018 1:47 pm GNW     ObsEva SA ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
  12:00 pm GNW     ObsEva SA ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
02 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
01 Mar 2018 12:00 pm GNW     ObsEva SA ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
26 Feb 2018 12:00 pm GNW     ObsEva SA ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
23 Feb 2018 9:00 pm GNW     ObsEva SA ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
07 Feb 2018 12:00 pm GNW     ObsEva SA ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
01 Feb 2018 12:00 pm GNW     ObsEva SA Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
05 Jan 2018 12:00 pm GNW     ObsEva SA ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018
 


Company Announcements Archive »

 
Headlines
Top categories

15-Jul-2019 04:13 PM

ADM Energy appoints Osamede Okhomina as CEO

Oil and gas investing company ADM Energy said it had appointed Osamede Okhomina as its new chief executive, with immediate effect. Okhomina replaced ...

More headlines
Company finder
Forthcoming announcements
Latest directors dealings

a d v e r t i s e m e n t